F4 Pharma, a clinical-stage biopharmaceutical company developing FX06, an anti-inflammatory therapeutic that has shown to improve vascular integrity, has included the first patient with severe COVID-19 in a study named “FX-COVID”, to confirm the efficacy and safety of FX06 in hospitalized patients receiving mechanical ventilation.
Read more
Pfizer’s and Biontech’s vaccine candidate for COVID-19 has met all the study’s primary efficacy endpoints.
Read more
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the European Union (EU) for the 1st-line maintenance treatment with bevacizumab of patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer.
Read more
Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent1
Read more
Gyroscope doses first patient in Phase II EXPLORE trial evaluating GT005 in people with geographic atrophy secondary to dry AMD with a mutation in the Complement Factor I gene.
Read more
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the completion of a €32 million Series B financing round.
Read more
NTG Nordic Transport Group increases the share capital to acquire remaining 15% of the shares in Ebrex Business Solutions Ltd.
Read more
Lille (France), Cambridge (Massachusetts, United States), July 7, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated
Read more
Data from Phase 3 LIBERTY program show improvement in patient-reported outcomes in addition to improvement in hemoglobin levels in anemic
Read more
Vetter and Rentschler Biopharma have announced joining forces to boost their services and along the biopharmaceutical value chain.
Read more